144 related articles for article (PubMed ID: 36602756)
1. Efficacy Endpoints in Phase II Clinical Trials for Meningioma: An Analysis of Recent Clinical Trials.
Watanabe S; Nonaka T; Maeda M; Sugii N; Hashimoto K; Takano S; Koyanagi T; Yamada M; Arakawa Y; Ishikawa E
Ther Innov Regul Sci; 2023 May; 57(3):603-610. PubMed ID: 36602756
[TBL] [Abstract][Full Text] [Related]
2. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
3. Recent Status of Phase I Clinical Trials for Brain Tumors: A Regulatory Science Study of Exploratory Efficacy Endpoints.
Watanabe S; Nonaka T; Maeda M; Yamada M; Sugii N; Hashimoto K; Takano S; Koyanagi T; Arakawa Y; Ishikawa E
Ther Innov Regul Sci; 2024 Mar; ():. PubMed ID: 38530629
[TBL] [Abstract][Full Text] [Related]
4. Phase II study of Gleevec® plus hydroxyurea (HU) in adults with progressive or recurrent meningioma.
Reardon DA; Norden AD; Desjardins A; Vredenburgh JJ; Herndon JE; Coan A; Sampson JH; Gururangan S; Peters KB; McLendon RE; Norfleet JA; Lipp ES; Drappatz J; Wen PY; Friedman HS
J Neurooncol; 2012 Jan; 106(2):409-15. PubMed ID: 21938530
[TBL] [Abstract][Full Text] [Related]
5. Trabectedin for recurrent WHO grade 2 or 3 meningioma: A randomized phase II study of the EORTC Brain Tumor Group (EORTC-1320-BTG).
Preusser M; Silvani A; Le Rhun E; Soffietti R; Lombardi G; Sepulveda JM; Brandal P; Brazil L; Bonneville-Levard A; Lorgis V; Vauleon E; Bromberg J; Erridge S; Cameron A; Lefranc F; Clement PM; Dumont S; Sanson M; Bronnimann C; Balaná C; Thon N; Lewis J; Mair MJ; Sievers P; Furtner J; Pichler J; Bruna J; Ducray F; Reijneveld JC; Mawrin C; Bendszus M; Marosi C; Golfinopoulos V; Coens C; Gorlia T; Weller M; Sahm F; Wick W
Neuro Oncol; 2022 May; 24(5):755-767. PubMed ID: 34672349
[TBL] [Abstract][Full Text] [Related]
6. Phase II trial of sunitinib for recurrent and progressive atypical and anaplastic meningioma.
Kaley TJ; Wen P; Schiff D; Ligon K; Haidar S; Karimi S; Lassman AB; Nolan CP; DeAngelis LM; Gavrilovic I; Norden A; Drappatz J; Lee EQ; Purow B; Plotkin SR; Batchelor T; Abrey LE; Omuro A
Neuro Oncol; 2015 Jan; 17(1):116-21. PubMed ID: 25100872
[TBL] [Abstract][Full Text] [Related]
7. Apatinib in recurrent anaplastic meningioma: a retrospective case series and systematic literature review.
Wang Y; Li W; Jing N; Meng X; Zhou S; Zhu Y; Xu J; Tao R
Cancer Biol Ther; 2020 Jul; 21(7):583-589. PubMed ID: 32212907
[TBL] [Abstract][Full Text] [Related]
8. Historical time to disease progression and progression-free survival in patients with recurrent/refractory neuroblastoma treated in the modern era on Children's Oncology Group early-phase trials.
London WB; Bagatell R; Weigel BJ; Fox E; Guo D; Van Ryn C; Naranjo A; Park JR
Cancer; 2017 Dec; 123(24):4914-4923. PubMed ID: 28885700
[TBL] [Abstract][Full Text] [Related]
9. Resampling phase III data to assess phase II trial designs and endpoints.
Sharma MR; Karrison TG; Jin Y; Bies RR; Maitland ML; Stadler WM; Ratain MJ
Clin Cancer Res; 2012 Apr; 18(8):2309-15. PubMed ID: 22287601
[TBL] [Abstract][Full Text] [Related]
10. Statistical considerations and endpoints for clinical lung cancer studies: Can progression free survival (PFS) substitute overall survival (OS) as a valid endpoint in clinical trials for advanced non-small-cell lung cancer?
Pilz LR; Manegold C; Schmid-Bindert G
Transl Lung Cancer Res; 2012 Mar; 1(1):26-35. PubMed ID: 25806152
[TBL] [Abstract][Full Text] [Related]
11. Everolimus and Octreotide for Patients with Recurrent Meningioma: Results from the Phase II CEVOREM Trial.
Graillon T; Sanson M; Campello C; Idbaih A; Peyre M; Peyrière H; Basset N; Autran D; Roche C; Kalamarides M; Roche PH; Fuentes S; Tabouret E; Barrie M; Cohen A; Honoré S; Boucekine M; Baumstarck K; Figarella-Branger D; Barlier A; Dufour H; Chinot OL
Clin Cancer Res; 2020 Feb; 26(3):552-557. PubMed ID: 31969329
[TBL] [Abstract][Full Text] [Related]
12. A phase II trial of bevacizumab and everolimus as treatment for patients with refractory, progressive intracranial meningioma.
Shih KC; Chowdhary S; Rosenblatt P; Weir AB; Shepard GC; Williams JT; Shastry M; Burris HA; Hainsworth JD
J Neurooncol; 2016 Sep; 129(2):281-8. PubMed ID: 27311730
[TBL] [Abstract][Full Text] [Related]
13. Recurrent high-grade meningioma: a phase II trial with somatostatin analogue therapy.
Simó M; Argyriou AA; Macià M; Plans G; Majós C; Vidal N; Gil M; Bruna J
Cancer Chemother Pharmacol; 2014 May; 73(5):919-23. PubMed ID: 24619496
[TBL] [Abstract][Full Text] [Related]
14. Alternate Endpoints for Phase II Trials in Advanced Neuroendocrine Tumors.
Imaoka H; Sasaki M; Takahashi H; Hashimoto Y; Ohno I; Mitsunaga S; Watanabe K; Umemoto K; Kimura G; Suzuki Y; Kan M; Ikeda M
Oncologist; 2019 Jan; 24(1):47-53. PubMed ID: 30072388
[TBL] [Abstract][Full Text] [Related]
15. Immune-Modified Response Evaluation Criteria In Solid Tumors (imRECIST): Refining Guidelines to Assess the Clinical Benefit of Cancer Immunotherapy.
Hodi FS; Ballinger M; Lyons B; Soria JC; Nishino M; Tabernero J; Powles T; Smith D; Hoos A; McKenna C; Beyer U; Rhee I; Fine G; Winslow N; Chen DS; Wolchok JD
J Clin Oncol; 2018 Mar; 36(9):850-858. PubMed ID: 29341833
[TBL] [Abstract][Full Text] [Related]
16. Proposed response assessment and endpoints for meningioma clinical trials: report from the Response Assessment in Neuro-Oncology Working Group.
Huang RY; Bi WL; Weller M; Kaley T; Blakeley J; Dunn I; Galanis E; Preusser M; McDermott M; Rogers L; Raizer J; Schiff D; Soffietti R; Tonn JC; Vogelbaum M; Weber D; Reardon DA; Wen PY
Neuro Oncol; 2019 Jan; 21(1):26-36. PubMed ID: 30137421
[TBL] [Abstract][Full Text] [Related]
17. Adoption of multiple primary endpoints in phase III trials of systemic treatments in patients with advanced solid tumours. A systematic review.
Zichi C; Paratore C; Gargiulo P; Mariniello A; Reale ML; Audisio M; Bungaro M; Caglio A; Gamba T; Perrone F; Di Maio M
Eur J Cancer; 2021 May; 149():49-60. PubMed ID: 33823362
[TBL] [Abstract][Full Text] [Related]
18. A Phase I/II Clinical Trial to evaluate the efficacy of baricitinib to prevent respiratory insufficiency progression in onco-hematological patients affected with COVID19: A structured summary of a study protocol for a randomised controlled trial.
Moreno-González G; Mussetti A; Albasanz-Puig A; Salvador I; Sureda A; Gudiol C; Salazar R; Marin M; Garcia M; Navarro V; de la Haba Vaca I; Coma E; Sanz-Linares G; Dura X; Fontanals S; Serrano G; Cruz C; Mañez R
Trials; 2021 Feb; 22(1):116. PubMed ID: 33546739
[TBL] [Abstract][Full Text] [Related]
19. Contemporary phase III clinical trial endpoints in advanced ovarian cancer: assessing the pros and cons of objective response rate, progression-free survival, and overall survival.
Tate Thigpen J
Gynecol Oncol; 2015 Jan; 136(1):121-9. PubMed ID: 25455732
[TBL] [Abstract][Full Text] [Related]
20. Validating ORR and PFS as surrogate endpoints in phase II and III clinical trials for NSCLC patients: difference exists in the strength of surrogacy in various trial settings.
Hua T; Gao Y; Zhang R; Wei Y; Chen F
BMC Cancer; 2022 Sep; 22(1):1022. PubMed ID: 36171546
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
